HC Wainwright Issues Pessimistic Outlook for OLMA Earnings

Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) – HC Wainwright reduced their Q3 2026 earnings per share estimates for shares of Olema Pharmaceuticals in a report released on Tuesday, August 11th. HC Wainwright analyst E. Bodnar now anticipates that the company will earn ($0.64) per share for the quarter, down from their previous estimate of ($0.58). HC Wainwright currently has a “Buy” rating and a $36.00 target price on the stock. The consensus estimate for Olema Pharmaceuticals’ current full-year earnings is ($2.22) per share. HC Wainwright also issued estimates for Olema Pharmaceuticals’ Q4 2026 earnings at ($0.67) EPS, FY2026 earnings at ($2.44) EPS, FY2027 earnings at ($2.78) EPS, FY2028 earnings at ($2.36) EPS, FY2029 earnings at ($1.69) EPS and FY2030 earnings at ($1.03) EPS.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings results on Monday, August 10th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.06).

Other analysts have also issued research reports about the stock. Wall Street Zen lowered shares of Olema Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, July 25th. Guggenheim dropped their target price on Olema Pharmaceuticals from $38.00 to $35.00 and set a “buy” rating on the stock in a report on Wednesday, May 13th. Weiss Ratings lowered Olema Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday, August 3rd. Finally, Citigroup decreased their price objective on shares of Olema Pharmaceuticals to $59.00 and set a “buy” rating for the company in a research note on Tuesday. Eleven research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $43.60.

Olema Pharmaceuticals Trading Up 0.1%

NASDAQ OLMA opened at $10.44 on Thursday. The company has a market capitalization of $913.50 million, a price-to-earnings ratio of -4.92 and a beta of 2.03. The company’s fifty day moving average price is $11.24 and its two-hundred day moving average price is $15.55. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.88 and a quick ratio of 10.88. Olema Pharmaceuticals has a 12 month low of $5.13 and a 12 month high of $36.26.

Insider Transactions at Olema Pharmaceuticals

In other news, Director Cyrus Harmon sold 12,500 shares of the business’s stock in a transaction on Thursday, July 23rd. The shares were sold at an average price of $11.58, for a total transaction of $144,750.00. Following the transaction, the director directly owned 715,270 shares in the company, valued at $8,282,826.60. The trade was a 1.72% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 12.56% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Olema Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in OLMA. EverSource Wealth Advisors LLC grew its holdings in shares of Olema Pharmaceuticals by 9,476.9% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,245 shares of the company’s stock worth $31,000 after purchasing an additional 1,232 shares in the last quarter. Torren Management LLC bought a new position in Olema Pharmaceuticals in the fourth quarter worth $44,000. Russell Investments Group Ltd. acquired a new stake in Olema Pharmaceuticals during the third quarter worth $53,000. American Century Companies Inc. bought a new stake in Olema Pharmaceuticals in the 2nd quarter valued at $54,000. Finally, Quantbot Technologies LP bought a new stake in Olema Pharmaceuticals in the 2nd quarter valued at $77,000. 91.78% of the stock is currently owned by institutional investors.

Olema Pharmaceuticals Company Profile

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.